Moreover, HER2 is thought to be a key driver of tumorigenesis in GC, and HER2-p status is suggested to be associated with the overall survival of the GC patient population, with poor outcomes might present in patients with HER2-p GC. This evidence concerns the gene ERBB2 and gastric cancer.